

# Jae Hoon Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8008916/publications.pdf>

Version: 2024-02-01

66  
papers

562  
citations

933447

10  
h-index

642732

23  
g-index

66  
all docs

66  
docs citations

66  
times ranked

1077  
citing authors

#	ARTICLE	IF	CITATIONS
1	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016, 127, 713-721.	1.4	121
2	Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 687-695.	1.8	85
3	A predictive model for risk of early grade 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , 2018, 32, 1404-1413.	7.2	53
4	Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. <i>International Journal of Hematology</i> , 2010, 92, 52-57.	1.6	41
5	Interim Report of Phase II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients with Disseminated Stage Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 2688-2688.	1.4	26
6	Head-to-Head Comparison of 5-Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome.. <i>Blood</i> , 2012, 120, 2843-2843.	1.4	23
7	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial.. <i>Blood</i> , 2008, 112, 3330-3330.	1.4	22
8	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , 2018, 59, 2305-2317.	1.3	18
9	Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin's Lymphoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 269-277.	1.0	14
10	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1.. <i>Blood</i> , 2011, 118, 3976-3976.	1.4	12
11	Factors affecting surgical outcomes of digital glomus tumour: a multicentre study. <i>Journal of Hand Surgery: European Volume</i> , 2018, 43, 652-658.	1.0	11
12	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 923-929.	2.0	10
13	Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 92-95.	1.3	10
14	Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. <i>Blood Research</i> , 2017, 52, 200.	1.3	9
15	Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8095-8095.	1.6	9
16	Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8510-8510.	1.6	9
17	A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1312-1319.	2.0	8
18	A comparison of fasciocutaneous and adipofascial methods in the reverse sural artery flap for treatment of diabetic infected lateral malleolar bursitis. <i>Journal of Orthopaedic Surgery</i> , 2019, 27, 230949901982854.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphoma with Breast Involvement; Multi-Institutional Analysis of 98 Patients in Korea.. Blood, 2009, 114, 5024-5024.	1.4	7
20	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.. Blood, 2009, 114, 743-743.	1.4	6
21	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. Cancer Medicine, 2017, 6, 100-108.	2.8	5
22	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). Annals of Hematology, 2020, 99, 309-319.	1.8	5
23	Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. Leukemia and Lymphoma, 2020, 61, 2714-2721.	1.3	5
24	Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1).. Journal of Clinical Oncology, 2012, 30, e18572-e18572.	1.6	5
25	Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. BioMed Research International, 2014, 2014, 1-7.	1.9	4
26	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE®, Thalidomide,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 47 Transplantation and Maintenance Treatment with VELCADE for Newly Diagnosed Multiple Myeloma: Interim Results of Phase II Trial.. Blood, 2007, 110, 952-952.	1.4	4
27	A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 MRI. Blood, 2008, 112, 3649-3649.	1.4	4
28	A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 488-488.	1.6	4
29	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. International Journal of Hematology, 2021, 113, 81-91.	1.6	3
30	Effect of herbal extracts on peripheral nerve regeneration after microsurgery of the sciatic nerve in rats. BMC Complementary Medicine and Therapies, 2021, 21, 162.	2.7	3
31	Onlay vascularized fibular grafting as a salvage procedure for the management of nonunion after reconstruction of the femur following tumor resection. Journal of Orthopaedic Surgery, 2018, 26, 230949901880249.	1.0	2
32	Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd). Therapeutic Advances in Hematology, 2020, 11, 204062072092104.	2.5	2
33	Efficacy of ICT with Deferasirox in Transfusional Iron Overloaded Patients with MDS or AA.. Blood, 2009, 114, 3810-3810.	1.4	2
34	Irinotecan and Cisplatin Combination Chemotherapy Plus Concurrent Thoracic Irradiation for Patients with Limited Disease Small Cell Lung Cancer. Journal of Lung Cancer, 2011, 10, 49.	0.2	1
35	A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera. Cancer Genetics, 2016, 209, 112-116.	0.4	1
36	The Assessment of IL-6R Gene Using FISH in MM.. Blood, 2007, 110, 4849-4849.	1.4	1

#	ARTICLE	IF	CITATIONS
37	A Multicenter Comparison of Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation with Tandem Autologous Stem Cell Transplantation in Multiple Myeloma.. Blood, 2007, 110, 940-940.	1.4	1
38	Bortezomib-Based Induction Therapy Induces Better Responses and Outcomes of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: The Results of Korean Multiple Myeloma Working Party Retrospective Study, KMM84. Blood, 2008, 112, 5184-5184.	1.4	1
39	Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. Blood, 2009, 114, 1792-1792.	1.4	1
40	The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotyping in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study.. Blood, 2009, 114, 4902-4902.	1.4	1
41	Osteonecrosis of the Jaw in Multiple Myeloma Patients: Incidence and Characteristics in Korean Patients.. Blood, 2009, 114, 4956-4956.	1.4	1
42	Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study.. Journal of Clinical Oncology, 2012, 30, 8097-8097.	1.6	1
43	A Multicenter, Phase III Clinical Trial of LeucogreenÂ®(G-CSF) for Chemotherapy-Induced Neutropenia in Solid Tumors. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2003, 11, 38.	0.1	1
44	A Phase 1/2, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan As a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: Result of Phase 1 Trial. Blood, 2012, 120, 1937-1937.	1.4	1
45	The Radiographic Risk Factors Predicting Occurrence of Idiopathic Carpal Tunnel Syndrome in Simple Wrist X-ray. Journal of Clinical Medicine, 2022, 11, 4031.	2.4	1
46	MTHFR 677CC/1298CC Genotypes Are Highly Associated with Chronic Myelogenous Leukemia: A Case-Control Study in Korea.. Blood, 2007, 110, 4533-4533.	1.4	0
47	VelcadeÂ®, Thalidomide, Dexamethasone (VTD) Induction Therapy Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment for the Patients (pts) with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Early Analysis from the Korean Multiple Myeloma Working Party.. Blood, 2007, 110, 4831-4831.	1.4	0
48	Varicella Zoster Virus Reactivation with the Use of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients.. Blood, 2007, 110, 4843-4843.	1.4	0
49	The Equal Activity of Azacytidine in 4 Risk Groups of IPSS in MDS.. Blood, 2007, 110, 4615-4615.	1.4	0
50	VelcadeÂ®, Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial. Blood, 2008, 112, 2785-2785.	1.4	0
51	Bortezomib, Doxorubicin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide and Dexamethasone (TD) as a Salvage Treatment for Relapsed Multiple Myeloma (MM): Analysis of Efficacy and Safety. Blood, 2008, 112, 5187-5187.	1.4	0
52	Final Report of "Korean Multicenter AML-2000 Trial" Intention to Treat Analysis Based on Cytogenetics Risk. Blood, 2008, 112, 2975-2975.	1.4	0
53	Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?. Blood, 2008, 112, 5146-5146.	1.4	0
54	Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. Blood, 2009, 114, 4881-4881.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Evaluation of Platelet Indices for Differential Diagnosis of Thrombocytosis by ADVIA 120.. Blood, 2009, 114, 4472-4472.	1.4	0
56	Mutational Analysis of N-Ras Proto-Oncogene in Acute Myeloid Leukemia: A Study of 70 Adult Korean Patients. Blood, 2011, 118, 4883-4883.	1.4	0
57	Relationship Between Intestinal Marginal Zone B-Cell Lymphoma and Enterobacterias Including Camphylobacter Jejuni. Blood, 2011, 118, 5224-5224.	1.4	0
58	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,. Blood, 2011, 118, 3989-3989.	1.4	0
59	A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, e14137-e14137.	1.6	0
60	A phase II trial of gemcitabine in combination with oxaliplatin and capecitabine in previously untreated metasetatic or recurrent pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, e14685-e14685.	1.6	0
61	High Dose Etoposide Plus G-CSF As an Effective Mobilization Regimen in Patients with NHL Previously Treated with R-CHOP or CHOP Chemotherapy. Retrospective Multicenter Study. Blood, 2012, 120, 1917-1917.	1.4	0
62	Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement.. Blood, 2012, 120, 2683-2683.	1.4	0
63	Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study. Blood, 2012, 120, 5035-5035.	1.4	0
64	A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3595-3595.	1.6	0
65	A phase II trial of a cremophor-free, polymeric micelle formulation of paclitaxel and gemcitabine in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, e19129-e19129.	1.6	0
66	Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 4421-4421.	1.4	0